Drug repurposing: from large-scale biological data to therapeutics

July 08, 2022
One of the challenges we are facing today is the high cost and slow pace of drug development for many disease areas such as cancer, CNS, rare diseases etc. Repurposing drugs for new indications will have a shorter developmental time, lower cost, and less safety risk than the traditional drug development process.

Join us for this 60-minute Webinar on Drug repurposing: from large-scale biological data to therapeutics. This one-hour event will show how our platform enables biologists to leverage transcriptomics and literature-curated biological data for in-silico drug repositioning and repurposing.

Through a series of short demonstrations, we will explore:
• A systems biology approach to discover new uses of existing FDA-approved drugs
• Accelerate drug discovery process and generate novel hypotheses from high-quality omics and literature curated data
• Estimate network of genes potentially perturbed by drugs and integrate it with drug and disease gene expression signatures
• Study how targets of interest are expressed across different diseases and tissues

Our system uses millions of curated literature findings in the QIAGEN/ IPA knowledgebase and the OmicSoft digital warehouse. The presentation is intended for both those familiar with Ingenuity Pathway and newcomers interested in learning more.

Related videos


Somatic variants investigation in critical regulatory pathways

125 views August 25, 2022

This training will focus on using QIAGEN Ingenuity Pathway analysis (IPA) and...


QIAGEN Ingenuity Pathway Analysis (IPA) for grant writing and publications with new features

167 views October 20, 2022

QIAGEN Ingenuity Pathway Analysis (IPA) represents a robust resource to aid...


Multi omics analysis using QIAGEN Ingenuity Pathway Analysis

361 views October 20, 2022

In this 90-minute training session you’ll learn about how QIAGEN Ingenuity...


IPA deeper dive Making most out of user’s core analysis and new features.mp4

236 views October 10, 2022

Many Ingenuity Pathway Analysis (IPA) users have requested a deeper dive...